Fig. 7
Comparison of efficacy and safety outcomes between 100 mg and 300 mg eptinezumab. a: monthly migraine days (MMDs); b: 75% responder rate; c: 50% responder rate; d: patients with migraine 1 day after dosing; e: treatment emergent adverse events (TEAEs)